ASH 2021 | Treating multiple myeloma in the UK
Martin Kaiser, MD, FRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, talks on the treatment approaches used for patients with multiple myeloma in the UK. Typically, fit patients are treated with bortezomib-thalidomide-dexamethasone (VTD) induction prior to stem cell transplantation and lenalidomide maintenance. Upon relapse, treatment options are decided based on the patient’s treatment history. For patients who are transplant-ineligible, lenalidomide-based or bortezomib-based regimens are commonly used. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
Currently, patients in the UK are eligible for treatment on the NHS and the NHS is really guiding us in terms of what treatment we can or cannot use and which line of therapy. So, for younger, fitter patients that is currently induction therapy with VTd transplant and then revlimid maintenance, which is actually backed up by data that was just generated from the most recent trial reported, the Myeloma XI trial...
Currently, patients in the UK are eligible for treatment on the NHS and the NHS is really guiding us in terms of what treatment we can or cannot use and which line of therapy. So, for younger, fitter patients that is currently induction therapy with VTd transplant and then revlimid maintenance, which is actually backed up by data that was just generated from the most recent trial reported, the Myeloma XI trial. Then at relapse, there are different options now that patients can go down, depending on what previous treatments they had. So, it becomes quite complicated immediately for the relapse therapies. The most common relapse therapy, however, is daratumumab, velcade, and dexamethasone. For the patients that are not fit enough for being treated with such intensive therapy as a transplant, these patients have access to either revlimid-based therapy or velcade-based therapy. Then again, there is a range of options depending on what they had at first line therapy as to what they can get at relapse.
Read more...
